[New EMA drug approval: Nivolumab in association with chemotherapy as first line treatment for HER2-negative esophageal adenocarcinoma with PD-L1 expression (CPS≥5)].
作者信息
Quesada Stanislas, Vaflard Pauline
机构信息
Institut régional du cancer de Montpellier (ICM), 208, avenue des Apothicaires, parc euromédecine, 34298 Montpellier cedex 5, France.
Institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France.
出版信息
Bull Cancer. 2022 Feb;109(2):109-110. doi: 10.1016/j.bulcan.2021.11.012. Epub 2022 Jan 4.
PMID:34996599
Abstract
摘要
Zotero 插件